The Board

Sarah Fredriksson, PhD, (Chairman):

PhD and M.Sc. from Lund University. CEO of P.U.L.S. AB. She has a background as founder and CEO of Genovis AB (listed on First North, Nasdaq OMX Nordic) and most recently CEO of Edvince AB. Currently board member of LU Holding and SwedenBio and other board member assignments in the life science sector as well as of Sparbankstiftelsen Skånes Riskkapitalstiftelse. Former board member of AcuCort AB.

Niklas Arnberg, PhD:

Professor, Dept. of Virology, Inst. Of Clinical Microbiology, University of Umeå, Sweden. Discovered that sialic acid is the receptor for certain adenoviruses and defended his doctorial thesis in this subject in 2001. Arnberg has continued his research within this field.

Clas Runnberg:

Market economist. Runnberg has held senior executive positions in several international medtech companies including Gambro and HemoCue in Sweden; Diatek Medical Technologies, Block Medical and HemoCue, Inc. in California, USA and Vidacare B.V. in the Netherlands. Presently he is an industrial advisor to the Swedish private equity fund Valedo, engaged in the Clinical Innovation Fellowships program at KTH, Stockholm and a board member at Medicon Bridge in Lund. Former chairman of P.U.L.S. AB.


Björn Dellgren:

M.Sc.(BA). Project leader for Adenovir Pharma AB. Former Partner at BankInvest, Denmark and have worked with international biotech venture investments and fund management since 2000. Previous Director of Business Development at Pharmacia and various international positions in sales, marketing and business management at Pharmacia and the American pharmaceutical company, Lederle. Currently board member in Cernelle AB, Sweden, previous board member in Cellectis SA, France and CMC Biologics, Denmark.